London specialist clinic Santis Health has received a 2026 Global Recognition Award for combining robotic prostatectomy, real-time pathology and multidisciplinary planning in prostate cancer care.
Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to ...
A phase 3 PROTEUS substudy published in European Urology reports that perioperative apalutamide plus hormone therapy around ...
A retrospective cohort study of 124 men with biopsy Gleason 6 prostate cancer found that elevated PSA density and perineural ...
Webcast and Conference Call Information PROCEPT BioRobotics will host a conference call to discuss the third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time.
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
What’s New On Radiotherapy of Prostate Cancer in 2026? / OncoDaily RT, prostate cancer, prostate cancer radiotherapy, ...
Proud to Share New PROTEUS Findings on Perioperative Treatment in High-Risk Prostate Cancer / A Douglas Laird, ADT, Alberto ...
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
Prostate cancer upgrading was independently associated with elevated PSA density and perineural invasion in a retrospective ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results